Literature DB >> 24371049

Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins.

Antonio Trabalza1, Ioanna Eleftheriadou, Argyro Sgourou, Ting-Yi Liao, Petros Patsali, Heyne Lee, Nicholas D Mazarakis.   

Abstract

UNLABELLED: To investigate the potential benefits which may arise from pseudotyping the HIV-1 lentiviral vector with its homologous gp41 envelope glycoprotein (GP) cytoplasmic tail (CT), we created chimeric RVG/HIV-1gp41 GPs composed of the extracellular and transmembrane sequences of RVG and either the full-length gp41 CT or C terminus gp41 truncations sequentially removing existing conserved motifs. Lentiviruses (LVs) pseudotyped with the chimeric GPs were evaluated in terms of particle release (physical titer), biological titers, infectivity, and in vivo central nervous system (CNS) transduction. We report here that LVs carrying shorter CTs expressed higher levels of envelope GP and showed a higher average infectivity than those bearing full-length GPs. Interestingly, complete removal of GP CT led to vectors with the highest transduction efficiency. Removal of all C-terminal gp41 CT conserved motifs, leaving just 17 amino acids (aa), appeared to preserve infectivity and resulted in a significantly increased physical titer. Furthermore, incorporation of these 17 aa in the RVG CT notably enhanced the physical titer. In vivo stereotaxic delivery of LV vectors exhibiting the best in vitro titers into rodent striatum facilitated efficient transduction of the CNS at the site of injection. A particular observation was the improved retrograde transduction of neurons in connected distal sites that resulted from the chimeric envelope R5 which included the "Kennedy" sequence (Ken) and lentivirus lytic peptide 2 (LLP2) conserved motifs in the CT, and although it did not exhibit a comparable high titer upon pseudotyping, it led to a significant increase in distal retrograde transduction of neurons. IMPORTANCE: In this study, we have produced novel chimeric envelopes bearing the extracellular domain of rabies fused to the cytoplasmic tail (CT) of gp41 and pseudotyped lentiviral vectors with them. Here we report novel effects on the transduction efficiency and physical titer of these vectors, depending on CT length and context. We also managed to achieve increased neuronal transduction in vivo in the rodent CNS, thus demonstrating that the efficiency of these vectors can be enhanced following merely CT manipulation. We believe that this paper is a novel contribution to the field and opens the way for further attempts to surface engineer lentiviral vectors and make them more amenable for applications in human disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24371049      PMCID: PMC3958067          DOI: 10.1128/JVI.03376-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides.

Authors:  M A Miller; R F Garry; J M Jaynes; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1991-06       Impact factor: 2.205

2.  Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.

Authors:  N D Mazarakis; M Azzouz; J B Rohll; F M Ellard; F J Wilkes; A L Olsen; E E Carter; R D Barber; D F Baban; S M Kingsman; A J Kingsman; K O'Malley; K A Mitrophanous
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

3.  Identification of the glycoprotein 41(TM) cytoplasmic tail domains of human immunodeficiency virus type 1 that interact with Pr55Gag particles.

Authors:  C Hourioux; D Brand; P Y Sizaret; F Lemiale; S Lebigot; F Barin; P Roingeard
Journal:  AIDS Res Hum Retroviruses       Date:  2000-08-10       Impact factor: 2.205

4.  Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.

Authors:  Stéphanie Wyss; Antony S Dimitrov; Frédéric Baribaud; Terri G Edwards; Robert Blumenthal; James A Hoxie
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail.

Authors:  T Murakami; E O Freed
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Direct interaction between the envelope and matrix proteins of HIV-1.

Authors:  P Cosson
Journal:  EMBO J       Date:  1996-11-01       Impact factor: 11.598

7.  Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.

Authors:  S R Bartz; M E Rogel; M Emerman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

Authors:  S Funke; I C Schneider; S Glaser; M D Mühlebach; T Moritz; R Cattaneo; K Cichutek; C J Buchholz
Journal:  Gene Ther       Date:  2009-02-12       Impact factor: 5.250

9.  Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity.

Authors:  K Zingler; D R Littman
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

10.  A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein.

Authors:  Rahel Byland; Patricia J Vance; James A Hoxie; Mark Marsh
Journal:  Mol Biol Cell       Date:  2006-11-15       Impact factor: 4.138

View more
  4 in total

1.  Rabies virus envelope glycoprotein targets lentiviral vectors to the axonal retrograde pathway in motor neurons.

Authors:  James N Hislop; Tarin A Islam; Ioanna Eleftheriadou; David C J Carpentier; Antonio Trabalza; Michael Parkinson; Giampietro Schiavo; Nicholas D Mazarakis
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

2.  Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins.

Authors:  Patrick L Sinn; Jeremy E Coffin; Natarajan Ayithan; Kathleen H Holt; Wendy Maury
Journal:  Methods Mol Biol       Date:  2017

3.  A Matter of Genes: The Hurdles of Gene Therapy for Epilepsy.

Authors:  Selene Ingusci; Stefano Cattaneo; Gianluca Verlengia; Silvia Zucchini; Michele Simonato
Journal:  Epilepsy Curr       Date:  2019-02-12       Impact factor: 7.500

Review 4.  Gene Therapy for ALS-A Perspective.

Authors:  Marisa Cappella; Chiara Ciotti; Mathilde Cohen-Tannoudji; Maria Grazia Biferi
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.